par Fumagalli, Debora 
;Wilson, T R;Salgado, Roberto;Lu, X;Yu, J;O'Brien, CO;Walter, K;Huw, L Y;Criscitiello, Carmen ;Laïos, Ioanna;Jose, Vinu ;Brown, David Norman ;Rothé, Françoise ;Maetens, Marion M. ;Zardavas, Dimitrios ;Savas, P;Larsimont, Denis ;Piccart-Gebhart, Martine ;Michiels, Stefan ;Lackner, Mark;Sotiriou, Christos ;Loi, Sherene
Référence Annals of oncology, 27, 10, page (1860-1866)
Publication Publié, 2016-10
;Wilson, T R;Salgado, Roberto;Lu, X;Yu, J;O'Brien, CO;Walter, K;Huw, L Y;Criscitiello, Carmen ;Laïos, Ioanna;Jose, Vinu ;Brown, David Norman ;Rothé, Françoise ;Maetens, Marion M. ;Zardavas, Dimitrios ;Savas, P;Larsimont, Denis ;Piccart-Gebhart, Martine ;Michiels, Stefan ;Lackner, Mark;Sotiriou, Christos ;Loi, Sherene Référence Annals of oncology, 27, 10, page (1860-1866)
Publication Publié, 2016-10
Article révisé par les pairs
| Résumé : | Estrogen receptor-positive (ER+) breast cancers (BCs) constitute the most frequent BC subtype. The molecular landscape of ER+ relapsed disease is not well characterized. In this study, we aimed to describe the genomic evolution between primary (P) and matched metastatic (M) ER+ BCs after failure of adjuvant therapy. |
